Quoin Pharma wins FDA fast track status for QRX003 in peeling skin syndrome

Bitget2026/09/22 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA granted Fast Track designation to Quoin’s QRX003 for Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.
Marks the first Fast Track designation for any Peeling Skin Syndrome therapy; QRX003 previously received Fast Track for Netherton Syndrome in March 2026.
Quoin plans to start a Phase 2/3 trial in 2H 2026; it is targeting approval in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220830PRIMZONEFULLFEED9830815) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quoin Pharma wins FDA fast track status for QRX003 in peeling skin syndrome

You may also like

Crypto prices